SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2020

Revenue by payor class as a percentage of total net service revenue is as follows:


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2020		2019		2020		2019
Home Health:
Medicare	41	%	43	%	41	%	44	%
Non-Medicare - Episodic-based	7	%	9	%	6	%	9	%
Non-Medicare - Non-episodic based	12	%	11	%	13	%	12	%
Hospice (1):
Medicare	35	%	31	%	34	%	30	%
Non-Medicare	2	%	2	%	2	%	1	%
Personal Care	3	%	4	%	4	%	4	%
	100	%	100	%	100	%	100	%
(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare on June 1, 2020.

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


	Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2020		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	311.5	$	—	$	317.2	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Three- Month Periods Ended September 30,		For the Nine- Month Periods Ended September 30,
	2020	2019	2020	2019
Weighted average number of shares outstanding - basic	32,662	32,211	32,469	32,096
Effect of dilutive securities:
Stock options	336	532	506	543
Non-vested stock and stock units	262	259	292	305
Weighted average number of shares outstanding - diluted	33,260	33,002	33,267	32,944
Anti-dilutive securities	36	133	31	154